AliveDx Overview
- Year Founded
-
2007

- Status
-
Public
- Employees
-
170

- Share Price
-
$0.13
- (As of Thursday Closing)
AliveDx General Information
Description
Manufacturer of conventional reagent products intended to help with blood grouping within the global transfusion diagnostics market. The company offers medical device, innovation, diagnostics, autoimmune diseases, in-vitro diagnostics, blood banking and disease screening.
Contact Information
Website
www.alivedx.comCorporate Office
- Business Park Terre Bonne
- Route de Crassier 13
- 1262 Eysins
- Switzerland
Corporate Office
- Business Park Terre Bonne
- Route de Crassier 13
- 1262 Eysins
- Switzerland
AliveDx Stock Performance
As of 15-Jun-2023, AliveDx’s stock price is $0.13. Its current market cap is $2.74M with 21.1M shares.
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.13 | $0.13 | $0.02 - $18.37 | $2.74M | 21.1M | 40.41 | -$36.62 |
AliveDx Financials Summary
As of 31-Dec-2022, AliveDx has a trailing 12-month revenue of $37.4M.
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
---|---|---|---|---|
EV | 248,911 | 294,504 | 444,549 | 378,844 |
Revenue | 37,410 | 38,514 | 43,379 | 32,656 |
EBITDA | (84,551) | (85,052) | (71,620) | (65,629) |
Net Income | (124,030) | (125,130) | (111,032) | (105,138) |
Total Assets | 119,326 | 193,989 | 219,812 | 226,738 |
Total Debt | 272,394 | 266,526 | 194,859 | 180,923 |
AliveDx Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
AliveDx Comparisons
Industry
Financing
Details
AliveDx Competitors (17)
One of AliveDx’s 17 competitors is Immucor, a Formerly PE-Backed company based in Norcross, GA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Immucor | Formerly PE-Backed | Norcross, GA | ||||
Bio-Rad Laboratories | Corporation | Hercules, CA | ||||
OncoCyte | Formerly VC-backed | Irvine, CA | ||||
Genomic Expression | Venture Capital-Backed | Beverly, MA | ||||
Abbott | Corporation | North Chicago, IL |
AliveDx Signals
AliveDx ESG
Risk Overview
Risk Rating
Updated January, 05, 2023
21.21 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,638
Rank
Percentile

Healthcare
Industry
of 636
Rank
Percentile

Medical Supplies
Subindustry
of 60
Rank
Percentile

AliveDx FAQs
-
When was AliveDx founded?
AliveDx was founded in 2007.
-
Where is AliveDx headquartered?
AliveDx is headquartered in Eysins, Switzerland.
-
What is the size of AliveDx?
AliveDx has 170 total employees.
-
What industry is AliveDx in?
AliveDx’s primary industry is Diagnostic Equipment.
-
Is AliveDx a private or public company?
AliveDx is a Public company.
-
What is the current stock price of AliveDx?
As of 15-Jun-2023 the stock price of AliveDx is $0.13.
-
What is the current market cap of AliveDx?
The current market capitalization of AliveDx is $2.74M.
-
What is AliveDx’s current revenue?
The trailing twelve month revenue for AliveDx is $37.4M.
-
Who are AliveDx’s competitors?
Immucor, Bio-Rad Laboratories, OncoCyte, Genomic Expression, and Abbott are some of the 17 competitors of AliveDx.
-
What is AliveDx’s annual earnings per share (EPS)?
AliveDx’s EPS for 12 months was -$36.62.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »